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OBJECTIVES To evaluate a possible effect of lipid lowering drugs on recurrences of ventricular arrhythmias
(VA) after implantable cardioverter defibrillator (ICD) implantation.
BACKGROUND In patients with coronary artery disease (CAD), lipid lowering drugs reduce total and sudden
cardiac death. Because the mechanism is not completely understood, we studied whether
these drugs have a favorable influence on the occurrence of life-threatening VA in patients
with CAD and ICD implants.
METHODS We conducted an observational study in 78 patients with CAD and life-threatening VA,
treated with an ICD. After ICD implantation, 27 patients were on treatment with lipid
lowering drugs (group I) and 51 were not (group II). Patients were studied for the following
end points: recurrences of VA requiring ICD intervention, cardiac death and hospitalization.
RESULTS After a mean follow-up of 490 6 319 days, 35 patients (45%) had recurrences of VA requiring
ICD intervention. In multivariate analysis, the use of lipid lowering drugs (chi-square 6.33,
p 5 0.012) and poorly tolerated sustained monomorphic ventricular tachycardia as initial
presentation (chi-square 4.84, p 5 0.028) remained as independent predictors of recurrences
of VA. Patients in groups I and II had similar baseline clinical characteristics, but patients in
group I had a lower incidence of recurrences of VA (6/27 or 22% vs. 29/51 or 57%, p 5 0.004)
and of the combined end points of cardiac death and hospitalization (4/27 or 15% vs. 23/51
or 45%, p 5 0.015) compared with patients in group II.
CONCLUSIONS This is the first observation that the use of lipid lowering drugs is associated with a reduction
of recurrences of VA in patients with CAD and ICD implants. These data require
confirmation in a prospective randomized trial. (J Am Coll Cardiol 2000;36:766–72) © 2000
by the American College of Cardiology
Sudden cardiac death affects more than 250,000 patients
yearly in the U.S., and in patients with coronary artery
disease (CAD) ventricular tachyarrhythmias are the major
cause of sudden cardiac death (1). Clinical and autopsy
studies (2–4) have clearly shown an association between
elevated cholesterol levels and sudden cardiac death. Fur-
thermore, secondary prevention trials have shown that lipid
lowering drugs reduce total and sudden cardiac death in
patients with CAD (5,6). Although several nongenomic
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mechanisms for lipid lowering drugs have recently been
claimed (7–10) and although ventricular tachyarrhythmias
are the major cause of sudden cardiac death in patients with
CAD, the possible effect of lipid lowering drugs on these
ventricular arrhythmias (VAs) is unknown.
The aim of this study is to evaluate a possible effect of
lipid lowering drugs on life-threatening VAs, including
ventricular tachycardia (VT) and ventricular fibrillation
(VF). Because an effect on VAs is difficult to document
accurately in the overall population of patients with CAD,
we studied a group of patients with CAD complicated with
life-threatening VAs that required treatment with a recent
generation implantable cardioverter defibrillator (ICD).
Since these devices can accurately document the nature and
the timing of recurrences of VAs, they allow a precise
follow-up after implantation. In this study, we evaluated
whether patients with lipid lowering therapy had fewer
recurrences of VAs after ICD implantation compared with
patients in whom lipid lowering drugs were not prescribed.
METHODS
Patient selection. We evaluated all consecutive patients
with CAD and life-threatening VAs who were admitted to
the Ghent University Hospital, Ghent, Belgium between
January 1995 and March 1998. After exclusion of patients
with VAs in the setting of acute myocardial infarction (MI)
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or significant electrolyte disturbances and after exclusion of
patients who were not inducible during electrophysiological
testing after revascularization (coronary artery bypass graft-
ing [CABG] or angioplasty), 78 patients were referred for
ICD implantation, who formed the study population.
The diagnosis of CAD was based on coronary angiogra-
phy, which showed obstructive CAD (.70% stenosis or
.50% stenosis for the left main coronary artery) in all
patients. Radionuclide angiography for the determination of
left ventricular ejection fraction was performed in all pa-
tients before the ICD implantation. Hemodynamically
poorly tolerated sustained monomorphic VT was the pre-
senting arrhythmia in 55 patients (70%); 20 patients (26%)
had a cardiac resuscitation including defibrillation without
electrocardiographic documentation of sustained monomor-
phic VT, and three patients (4%) had a history of syncope
with inducible VAs at electrophysiological testing with the
use of a protocol described previously (11). Thirteen pa-
tients (17%) were revascularized at the time of ICD im-
plantation; 12 patients had CABG and one coronary an-
gioplasty. In all patients a tiered-therapy ICD device that
was capable of storing electrograms was implanted trans-
venously.
Lipid lowering drugs. The decision to treat patients with
lipid lowering drugs and the choice of treatment with statins
or fibrates was at the discretion of the referring physician.
During the study period, the Belgian reimbursement regu-
lation for lipid lowering drugs (total cholesterol .250 mg/dl
after three months of adequate diet) was unchanged. In
total, 27 patients were on lipid lowering drugs at discharge
after ICD implantation (group I): 16 (59%) patients were on
statins and 11 (41%) on fibrates. Most of the patients in
group I (24 or 89%) were already on lipid lowering drugs
before the first presenting arrhythmia occurred. For the
three remaining patients, lipid lowering drugs were started
during the hospitalization for ICD implantation. The other
51 patients (group II) were not on lipid lowering drugs
before or after ICD implantation.
Cholesterol, high-density lipoprotein (HDL) cholesterol
and triglyceride levels were determined at the time of ICD
implantation and at the end of follow-up by commercially
available assays. Low-density lipoprotein (LDL) cholesterol
levels were calculated according to the formula of Friede-
wald (LDL cholesterol 5 total cholesterol 2 HDL choles-
terol 2 triglycerides/5).
Follow-up procedure. Per protocol, patients were seen and
ICDs interrogated one month after ICD implantation and
every three months thereafter. In the event of a shock or
hospitalization, an additional ICD interrogation was per-
formed. Patients were followed from the day of ICD
implantation until the first recurrence of VAs, death or
heart transplantation. Predefined study end points for re-
currences of VAs were documented episodes of ICD inter-
vention by antitachycardia pacing (ATP) or shocks for VAs.
Episodes of inappropriate ICD therapy due to supraventric-
ular arrhythmias, device malfunction, oversensing, lead
problems and sinus tachycardia were excluded from the data
analysis.
During the study period, hospitalization for cardiac
reasons was analyzed. Definitions for cardiac hospitalization
were one of the following: hospitalization for electrical
storm (defined as three or more appropriate ICD interven-
tions within 24 h) (12,13) with or without heart failure or
angina, hospitalization for heart failure or hospitalization
for angina. Information on all hospitalizations and deaths
during follow-up was obtained by contacts with the pa-
tients, family members or treating physicians and review of
medical records. All hospitalizations and deaths had to be
documented. This study protocol was approved by the
Ethical Committee of the Ghent University Hospital
(Study Project 011D0698).
Statistical analysis. The SPSS 7.5 for Windows statistical
package (SPSS for Windows, release 7.5, SPSS Inc., Chi-
cago, Illinois) was used for data analysis. All data are
reported as mean 6 SD, mean 6 SEM or total number (%).
Comparisons between the groups with and without lipid
lowering drugs and the groups with and without recurrences
of VAs requiring ICD intervention were made using the
unpaired Student t test for continuous variables and the
Fisher exact test for discrete variables. A multivariate
forward stepwise regression analysis was performed on the
parameters that were significantly associated with recur-
rences of VAs in univariate analysis.
Event-free survival curves were generated by the Kaplan-
Meier method, starting from the day of implantation.
Differences between event-free survival curves were assessed
using the log-rank method. Comparison between the total
cholesterol and LDL cholesterol levels were made using the
unpaired Student t test for the differences between groups
and the paired Student t test for the differences between the
start and end of follow-up. A p value ,0.05 was considered
as statistically significant.
RESULTS
Baseline characteristics. The study population consisted
of 78 patients with CAD and VAs, requiring ICD treat-
ment. Baseline characteristics for the total group and groups
Abbreviations and Acronyms
ATP 5 antitachycardia pacing
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
HDL 5 high-density lipoprotein
ICD 5 implantable cardioverter defibrillator
LDL 5 low-density lipoprotein
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
VA 5 ventricular arrhythmia
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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I (lipid lowering drugs at discharge) and II (no lipid
lowering drugs at discharge) are shown in Table 1. Both
groups were comparable for all parameters evaluated. The
majority of the patients had a clinical history of an acute MI
(n 5 53, 68%); ten of them (19%) had an acute MI within
one month before the occurrence of the presenting VA.
However, no patient had his presenting arrhythmia earlier
than five days after the onset of acute MI. The median time
interval between the MI and the occurrence of the initial
arrhythmic event was 120 months (range: 1 to 276 months).
The median time interval between the start of lipid lowering
therapy and the occurrence of the initial arrhythmic event in
the 24 patients who were already on lipid lowering therapy
before the initial arrhythmic event was 24 months (range: 3
to 50 months).
During the electrophysiological study the induced ar-
rhythmia was sustained monomorphic VT in 61 patients
(78%), polymorphic VF or tachycardia in 15 patients (19%),
and two patients (3%) were noninducible. The medication
at discharge for both groups is also presented in Table 1. No
significant differences were noted between both groups, and
no significant changes were seen between the medication at
discharge and at the end of follow-up procedures.
Predictors of recurrences of VAs requiring ICD inter-
vention during follow-up procedures. After a mean
follow-up of 490 6 319 days (range, 21 to 1,120 days), 35
patients (45%) had recurrences of VAs that were treated by
the ICD (ATP or shock). The remaining 43 patients (55%)
had no recurrences of VAs. As shown in Table 2, patients
Table 1. Baseline Characteristics and Medication at Discharge for the Total Group, Groups I
and II
Total Group
(n 5 78)
Group I (n 5 27)
Lipid Lowering
Drugs
Group II (n 5 51)
No Lipid
Lowering Drugs
Age (yrs) 66 6 9 65 6 10 66 6 9
Men/women 73/5 24/3 49/2
History of diabetes 10 (13%) 3 (11%) 7 (14%)
History of smoking 54 (69%) 19 (70%) 35 (69%)
History of hypertension 30 (38%) 12 (44%) 18 (35%)
Previous infarction 53 (68%) 20 (74%) 33 (65%)
Previous CABG or PTCA 22 (28%) 7 (26%) 15 (29%)
LVEF (%) 34 6 13 34 6 10 33 6 14
Clinical presentation
SMVT 55 (70%) 20 (74%) 35 (69%)
Cardiac resuscitation 20 (26%) 5 (19%) 15 (29%)
Syncope 3 (4%) 2 (7%) 1 (2%)
PTCA or CABG at ICD implantation 13 (17%) 4 (15%) 9 (18%)
Medication at discharge
ACE inhibitors 69 (88%) 23 (85%) 46 (90%)
Beta-blockers* 40 (51%) 17 (63%) 23 (45%)
Aspirin 61 (78%) 24 (89%) 37 (73%)
Digoxin 17 (22%) 5 (19%) 12 (24%)
Nitrates 28 (36%) 13 (48%) 15 (29%)
Sotalol 12 (15%) 3 (11%) 9 (18%)
Amiodarone 12 (15%) 4 (15%) 8 (16%)
Duration of follow-up (days) 490 6 319 475 6 292 510 6 331
Data are as mean 6 SD or total number (%). No significant differences were noted between groups I and II.
*Except sotalol.
ACE 5 angiotensin converting enzyme; CABG 5 coronary artery bypass grafting; LVEF 5 left ventricular ejection fraction;
PTCA 5 percutaneous transluminal coronary angioplasty; SMVT 5 sustained monomorphic ventricular tachycardia; VF 5
ventricular fibrillation.
Table 2. Univariate Predictors of Recurrences of Ventricular
Arrhythmias Requiring ICD Intervention During Follow-up
No ICD
Intervention
During Follow-up
(n 5 43)
ICD
Intervention
During Follow-up
(n 5 35)
p
Value
Age (yrs) 66 6 8 65 6 10 0.687
Men/women 40/3 33/2 0.999
Previous infarction 30 (70%) 23 (66%) 0.999
LVEF (%) 35 6 12 33 6 13 0.897
Clinical presentation
of SMVT
26 (60%) 29 (83%) 0.045
Medication at discharge
ACE-inhibitors 39 (91%) 30 (86%) 0.742
Beta-blockers* 28 (65%) 12 (34%) 0.012
Aspirin 37 (86%) 24 (69%) 0.097
Digoxin 8 (19%) 9 (26%) 0.583
Nitrates 13 (30%) 15 (43%) 0.343
Sotalol 5 (12%) 7 (20%) 0.356
Amiodarone 7 (16%) 5 (14%) 0.999
Cholesterol lowering
drugs
21 (49%) 6 (17%) 0.004
Data are as mean 6 SD or total number (%).
*Except sotalol.
ACE 5 angiotensin converting enzyme; LVEF 5 left ventricular ejection fraction;
SMVT 5 sustained monomorphic ventricular tachycardia.
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with recurrences of VA requiring ICD intervention during
follow-up had a hemodynamically poorly tolerated sustained
monomorphic VT more frequently as a presenting arrhyth-
mia before ICD implantation. Also, at discharge these
patients were significantly less frequently on beta-adrenergic
blocking agent therapy. Finally, a highly significant differ-
ence was found between both groups for the number of
patients on lipid lowering drugs at discharge (49% for
patients without recurrences of VAs vs. 17% for patients
with recurrences of VAs, p 5 0.004).
When entering the use of lipid lowering drugs first in
stepwise multivariate analysis, only the use of lipid lowering
drugs (chi-square 6.33, p 5 0.012) and hemodynamically
poorly tolerated sustained monomorphic VT as presenting
arrhythmia (chi-square 4.84, p 5 0.028) remained as
independent predictors of recurrences of VAs requiring
ICD intervention. Treatment with beta-blockers did not
prove to be an independent predictor of recurrences of VAs
requiring ICD intervention (chi-square 1.08, p 5 0.298).
When entering treatment with beta-blockers first in step-
wise multivariate analysis, the use of lipid lowering drugs
still remained an independent significant predictor for
recurrences of VAs requiring ICD intervention.
Outcome in patients with and without lipid lowering
drugs at discharge. As shown in Table 3, patients on lipid
lowering drugs had a significantly lower incidence of recur-
rences of VAs requiring ICD intervention. Kaplan-Meier
arrhythmia-free survival curves for the patients with and
without lipid lowering drugs at discharge are shown in
Figure 1A. When only the 40 patients on beta blockers at
discharge were considered, Kaplan-Meier arrhythmia-free
survival curves for the patients with (n 5 17) and without
lipid lowering drugs (n 5 23) at discharge were still
statistically significant (p 5 0.03), with significantly less
recurrences of VAs in the patients with lipid lowering drugs
at discharge (Fig. 2).
During the follow-up period, one patient underwent a
cardiac transplantation. Eleven other patients died: two
deaths were considered noncardiac (one acute massive
pulmonary embolism, confirmed at autopsy and one gastro-
intestinal bleeding), and nine were considered cardiac. An
additional 17 patients were hospitalized for cardiac reasons:
eight patients (47%) were hospitalized for three or more
appropriate ICD interventions within the previous 24 h
(electrical storm) and nine (53%) patients for heart failure or
recurrent angina. As is shown in Table 3, the frequency of
cardiac hospitalization and the combined end point of
Table 3. Outcome in Patients With (Group I) and Without
(Group II) Lipid Lowering Drugs
Group I
(n 5 27)
Lipid Lowering
Drugs
Group II
(n 5 51)
No Lipid
Lowering Drugs
p
Value
ICD therapy for VT or VF 6 (22%) 29 (57%) 0.004
ICD therapy for fast VT 3 (11%) 18 (35%) 0.032
Total death or heart
transplantation
3 (11%) 9 (18%) 0.528
Cardiac death or heart
transplantation
2 (8%) 8 (16%) 0.479
Cardiac hospitalization 2 (8%) 15 (29%) 0.041
Heart failure/angina 1 (4%) 8 (16%) 0.152
Electrical storm 1 (4%) 7 (13%) 0.250
Combined cardiac death
or cardiac hospitalization
4 (15%) 23 (45%) 0.015
Data are as total number (%).
Fast VT 5 ventricular arrhythmia with cycle length #300 ms; ICD 5 internal
cardioverter defibrillator; VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
Figure 1. (A) Kaplan-Meier arrhythmia-free survival for the patients with
and without lipid lowering drugs at discharge. (B) Kaplan-Meier cardiac
death or hospitalization-free survival for the patients with and without lipid
lowering drugs at discharge. ICD 5 internal cardioverter defibrillator;
VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
Figure 2. Kaplan-Meier arrhythmia-free survival for the patients on
beta-blockers (n 5 40) with and without lipid lowering drugs at discharge.
VT 5 ventricular tachycardia; VF 5 ventricular fibrillation.
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cardiac death or hospitalization were lower in the group of
patients with lipid lowering drugs at discharge. Kaplan-
Meier cardiac death or hospitalization-free survival curves
for the patients with and without lipid lowering drugs at
discharge are shown in Figure 1B.
Total and LDL cholesterol levels at discharge and at the
end of follow-up. As shown in Figure 3A, total cholesterol
levels for groups I and II were comparable at discharge
(192 6 47 vs. 215 6 50 mg/dl, p 5 0.119). At the end of
follow-up, cholesterol levels were significantly higher in
group II than they were in group I (254 6 47 vs. 213 6
25 mg/dl, p 5 0.004), although in group I there was also a
small, but significant, rise in cholesterol levels compared
with the values at discharge (213 6 25 vs. 192 6 47 mg/dl,
p 5 0.005).
Similar findings for LDL cholesterol levels are shown in
Figure 3B: LDL cholesterol levels were comparable at
discharge (122 6 47 vs. 132 6 37 mg/dl, p 5 0.419). At the
end of follow-up LDL cholesterol levels were significantly
higher in group II than they were in group I (172 6 40 vs.
139 6 23 mg/dl, p 5 0.015) although a small but significant
rise was also noted in group I compared with the values at
discharge (139 6 23 vs. 122 6 47 mg/dl, p 5 0.016).
DISCUSSION
This is the first study suggesting that lipid lowering drugs
are associated with a reduction of recurrences of VAs in
patients with CAD and life-threatening VAs treated with
ICD implantation.
Possible mechanisms. As was pointed out in a recent
overview by Mehta et al. (1), sudden death due to CAD can
be caused by VAs due to acute myocardial ischemia or to
reentrant arrhythmias in the setting of myocardial scar
tissue. Both mechanisms are, however, not mutually exclu-
sive. In the presence of scar tissue for example, several
triggers, including episodes of myocardial ischemia and
changes in autonomic tone, can modify the characteristics of
the substrate, making recurrences of VAs possible (14–17).
Although a direct effect of lipid lowering drugs on reentry
circuits can be a possible explanation for our findings, it is
more likely that lipid lowering drugs reduced the number of
ischemic episodes that could have acted as a trigger on the
myocardial substrate to initiate recurrences of VAs. The use
of statins could have prevented new episodes of myocardial
ischemia by several mechanisms, including stabilization of
vulnerable plaques, amelioration of endothelial dysfunction
and reduction of platelet reactivity (10). Fibrates target
primarily triglyceride-rich lipoproteins and HDL choles-
terol. Nonetheless, like the statins, fibrates could have
influenced the process of atherosclerosis by their effect on
the inflammatory response in patients with atherosclerosis
(18). Furthermore, fibrates could have played a role in the
improvement of the microcirculation by decreasing fibrin-
ogen and plasma viscosity (19,20). Although all these
possible anti-ischemic mechanisms could have contributed
to the reduced reoccurrence of VAs during follow-up,
further studies are needed to explain our findings.
Comparison to secondary prevention trials with lipid
lowering drugs. Regardless of the underlying mechanism,
our findings give a possible additional explanation for the
impressive reduction in mortality by lipid lowering drugs in
patients with a previous MI (5,6). In these trials, apart from
prevention of new MIs causing cardiac death, lipid lowering
could also have prevented new episodes of myocardial
ischemia that acted as a trigger on the substrate of potential
life-threatening VAs, namely the scar tissue caused by
previous infarction. In a subanalysis of the Long-term
Intervention with Pravastatin in Ischemic Disease (LIPID)
study, the incidence of sudden coronary death was only
moderately reduced from 4.7% to 4.0% by pravastatin (6).
However, patients at high risk for VAs with a recent ICD
implant were excluded in the LIPID study making a
comparison of the end point of sudden cardiac death
difficult. Also, our outcome curves start to diverge very early
after ICD implantation. This is in contrast to secondary
prevention trials with cholesterol lowering drugs in which
the outcome curves do not separate appreciably until 1 to 2
years after initiation of treatment (5,6,21). Recent studies,
however, have shown that lipid lowering can improve
Figure 3. (A) Total cholesterol values (mean 6 SEM) for the patients with
and without lipid lowering drugs at discharge and at the end of follow-up.
**p , 0.01. (B) LDL cholesterol values (mean 6 SEM) for the patients
with and without lipid lowering drugs at discharge and at the end of the
follow-up. **p , 0.01; *p , 0.05.
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endothelial function within four to six weeks in patients
with stable CAD (22) and in patients with unstable angina
or MI (23,24). Furthermore, lipid lowering can reduce
platelet thrombus deposition in hypercholesterolemic pa-
tients within 2.5 months of therapy to a level similar to that
of patients with normal lipid levels (9). Finally, clinical trials
such as the Myocardial Ischemia Reduction with Aggressive
Cholesterol Lowering (MIRACL) trial (25) are currently
evaluating short-term effects of aggressive lipid lowering in
patients with acute coronary syndromes. It is possible that in
our group of high-risk patients, effects on endothelial
function and platelets played a role in the observed early
effect on recurrences of VAs.
Although this study was not designed to evaluate effects
on total or cardiac mortality, the combined end point of
cardiac death and hospitalization was significantly lower in
the group of patients on lipid lowering drugs. These results
are in agreement with larger secondary prevention trials that
have shown that lipid lowering drugs reduce cardiac mor-
tality and morbidity after MI (5,6). Furthermore, patients
on lipid lowering drugs showed a trend towards reduction of
episodes of electrical storm. As pointed out by Credner et al.
(12), myocardial ischemia is probably one of the most
important precipitating factors for the electrical instability
in this potentially life-threatening syndrome after ICD
implantation.
Effects of beta-blockers. In this study, beta-blocker treat-
ment is associated in univariate analysis with a later occur-
rence of VAs requiring ICD intervention. Our results are in
agreement with previous studies (26–28) although placebo
controlled randomized studies on the effectiveness of beta-
blocker therapy in patients with VT or VF and ICD
implants are not available. Different mechanisms, including
an antagonizing effect on the effect of catecholamines,
anti-ischemic properties and a possible increase of the
threshold for VF, can explain this association (29–31).
However, lipid-lowering drugs were still associated with
fewer recurrences of VAs if only the patients who received
beta-blockers at discharge were analyzed (Fig. 2). This
suggests, together with the results of our multivariate
analysis, an independent effect of lipid lowering drugs in our
study population.
Clinical implications. In previous trials on the use of ICD
in patients with CAD, only a limited number of patients
were treated with lipid lowering drugs (32,33). Although in
our study total cholesterol and LDL cholesterol levels were
comparable at the moment of ICD implantation, most of
the patients who were not treated with lipid lowering drugs
showed a sharp increase in lipid levels, requiring lipid
lowering therapy according to actual guidelines (34,35).
These data indicate that, apart from the observed effect on
recurrences of VAs, lipid lowering drugs are probably
underused as secondary prevention after ICD implantation.
A practical consequence of our observations is also that the
decision to treat ICD patients with lipid lowering drugs
should not only be based on a lipoprotein analysis at the
moment of ICD implantation but also on a control lipopro-
tein analysis performed at early follow-up. A possible
explanation for the lower total and LDL cholesterol levels at
implantation compared with the levels at follow-up in both
groups is that a considerable number of patients in both
groups were recovering from reanimation or pneumonia,
factors known to induce an acute phase response, causing a
reduction in lipid levels (36).
Study limitations. The major limitation of this study was
that it was an observational study and not a randomized trial
for the evaluation of the effect of lipid lowering drugs on the
recurrence of VAs. Although the use of lipid lowering drugs
was strongly and independently associated with fewer re-
currences of VAs and although the groups with and without
lipid lowering drugs at discharge had similar clinical char-
acteristics, our findings need confirmation in a prospective
randomized trial.
Due to the limited number of patients, we could not
evaluate whether the effect on recurrence of VAs was more
pronounced in patients on statins or fibrates or on a specific
lipid lowering drug.
Left ventricular ejection fraction was not predictive for
recurrences of VAs. Although this may reflect the small
sample size of our study population, our results are in
agreement with the findings of Narasimhan et al. (37), who
reported on a larger group of patients with CAD (n 5 438)
and found no significant difference in occurrence of appro-
priate ICD shocks between patients with an ejection frac-
tion #20% (n 5 117) and an ejection fraction between 20%
and 41% (n 5 321).
Finally, these study results should not be extrapolated to
all patients who sustained an MI. However, it would be
interesting to further document (e.g., by Holter monitoring)
a possible effect of lipid lowering drugs on the occurrence of
VAs after MI since this could further contribute to the risk
stratification for sudden cardiac death after MI.
Conclusions. Lipid lowering drugs are associated with a
reduction of recurrences of VAs after ICD implantation in
patients with CAD and life-threatening VAs. Although the
possible mechanisms remain to be elucidated, the results of
this study indicate that intensive screening and adequate
treatment of hypercholesterolemia should be one of the
cornerstones of medical therapy in patients with CAD and
ICD implants. Finally, further randomized and prospective
studies are needed to confirm our findings and to evaluate
the potential effect of lipid lowering drugs on VAs in the
overall population of patients with CAD.
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